+

WO2012052478A3 - Composition de gel topique - Google Patents

Composition de gel topique Download PDF

Info

Publication number
WO2012052478A3
WO2012052478A3 PCT/EP2011/068261 EP2011068261W WO2012052478A3 WO 2012052478 A3 WO2012052478 A3 WO 2012052478A3 EP 2011068261 W EP2011068261 W EP 2011068261W WO 2012052478 A3 WO2012052478 A3 WO 2012052478A3
Authority
WO
WIPO (PCT)
Prior art keywords
topical gel
gel composition
paraben
gel compositions
treatment
Prior art date
Application number
PCT/EP2011/068261
Other languages
English (en)
Other versions
WO2012052478A2 (fr
Inventor
Jean-Christophe Buge
Karine Nadau Fourcade
Cyril Meunier
Original Assignee
Galderma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1058611A external-priority patent/FR2966365B1/fr
Priority to AU2011317642A priority Critical patent/AU2011317642A1/en
Priority to KR1020137012906A priority patent/KR20130101552A/ko
Priority to JP2013534308A priority patent/JP2013540142A/ja
Priority to SG2013026679A priority patent/SG189338A1/en
Priority to RU2013123043/15A priority patent/RU2013123043A/ru
Priority to PH1/2013/500679A priority patent/PH12013500679A1/en
Priority to EP11771146.5A priority patent/EP2605753A2/fr
Priority to CN2011800509124A priority patent/CN103313700A/zh
Priority to MX2013004472A priority patent/MX2013004472A/es
Priority to BR112013009577A priority patent/BR112013009577A2/pt
Application filed by Galderma S.A. filed Critical Galderma S.A.
Priority to CA2814975A priority patent/CA2814975A1/fr
Publication of WO2012052478A2 publication Critical patent/WO2012052478A2/fr
Publication of WO2012052478A3 publication Critical patent/WO2012052478A3/fr
Priority to ZA2013/02812A priority patent/ZA201302812B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions de gel topique améliorées, telles que celles qui contiennent de la brimonidine pour traiter des troubles cutanés. Ces compositions de gel contiennent les composants carbomère et parabène et sont sensiblement dépourvues de particules cristallines de parabène après une période de stockage prolongée.
PCT/EP2011/068261 2010-10-21 2011-10-19 Composition de gel topique WO2012052478A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2814975A CA2814975A1 (fr) 2010-10-21 2011-10-19 Composition de gel topique
EP11771146.5A EP2605753A2 (fr) 2010-10-21 2011-10-19 Composition de gel topique
JP2013534308A JP2013540142A (ja) 2010-10-21 2011-10-19 局所ゲル組成物
SG2013026679A SG189338A1 (en) 2010-10-21 2011-10-19 Topical gel composition
RU2013123043/15A RU2013123043A (ru) 2010-10-21 2011-10-19 Гелевая композиция для местного применения
PH1/2013/500679A PH12013500679A1 (en) 2010-10-21 2011-10-19 Topical gel composition
MX2013004472A MX2013004472A (es) 2010-10-21 2011-10-19 Composicion topica de gel.
AU2011317642A AU2011317642A1 (en) 2010-10-21 2011-10-19 Topical gel composition
CN2011800509124A CN103313700A (zh) 2010-10-21 2011-10-19 外用凝胶剂组合物
BR112013009577A BR112013009577A2 (pt) 2010-10-21 2011-10-19 composição de gel tópico e método
KR1020137012906A KR20130101552A (ko) 2010-10-21 2011-10-19 국소용 겔 조성물
ZA2013/02812A ZA201302812B (en) 2010-10-21 2013-04-18 Topical gel composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40538210P 2010-10-21 2010-10-21
US61/405,382 2010-10-21
FR1058611A FR2966365B1 (fr) 2010-10-21 2010-10-21 Composition de gel topique
FR1058611 2010-10-21

Publications (2)

Publication Number Publication Date
WO2012052478A2 WO2012052478A2 (fr) 2012-04-26
WO2012052478A3 true WO2012052478A3 (fr) 2012-06-14

Family

ID=45065557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/068261 WO2012052478A2 (fr) 2010-10-21 2011-10-19 Composition de gel topique

Country Status (14)

Country Link
EP (1) EP2605753A2 (fr)
JP (1) JP2013540142A (fr)
KR (1) KR20130101552A (fr)
CN (1) CN103313700A (fr)
AU (1) AU2011317642A1 (fr)
BR (1) BR112013009577A2 (fr)
CA (1) CA2814975A1 (fr)
IL (1) IL225775A0 (fr)
MX (1) MX2013004472A (fr)
PH (1) PH12013500679A1 (fr)
RU (1) RU2013123043A (fr)
SG (1) SG189338A1 (fr)
WO (1) WO2012052478A2 (fr)
ZA (1) ZA201302812B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140074883A (ko) * 2011-07-14 2014-06-18 알러간, 인코포레이티드 옥시메타졸린의 겔 조성물들 및 사용 방법
CN104666239A (zh) * 2013-11-27 2015-06-03 杭州赛利药物研究所有限公司 酒石酸溴莫尼定凝胶及其制备方法
CN103919717A (zh) * 2014-04-15 2014-07-16 天津中医药大学 一种酒石酸溴莫尼定眼用凝胶制剂及其制备方法和用途
US10744135B2 (en) * 2016-06-28 2020-08-18 Doris Maria HEXSEL Use of an active substance in the treatment of melasma
CN113784712A (zh) 2019-05-01 2021-12-10 克雷西奥生物科技有限公司 治疗瘙痒的方法
CN110882211A (zh) * 2019-12-31 2020-03-17 深圳市瀚德标检生物工程有限公司 一种羟苯酯类凝胶剂及其制备方法
CN116159018B (zh) * 2023-03-01 2024-11-01 中国药科大学 一种新型外用溴莫尼定凝胶剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009082452A1 (fr) * 2007-12-21 2009-07-02 Dejovin Jack A Traitement pré-chirurgical

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006A (en) * 1852-06-08 Improvement in seed-planters
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
WO2005115395A2 (fr) * 2004-05-25 2005-12-08 Sansrosa Pharmaceutical Development, Inc. Composes, preparations et methodes permettant de traiter ou de prevenir des troubles inflammatoires cutanes
TR201901431T4 (tr) 2007-11-16 2019-02-21 Aclaris Therapeutics Inc Purpura tedavisi için bileşimler ve yöntemler.
JP5052558B2 (ja) * 2009-04-03 2012-10-17 ロート製薬株式会社 ゲル軟膏

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009082452A1 (fr) * 2007-12-21 2009-07-02 Dejovin Jack A Traitement pré-chirurgical

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERMAN L. PERLOVICH, SERGEY V. RODIONOV, ANNETTE BAUER-BRANDL: "Thermodynamics of solubility, sublimation and solvation processes of parabens", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 24, 11 November 2004 (2004-11-11), pages 25 - 33, XP002631269 *
GIORDANO F, BETTINI R, DONINI C, GAZZANIGA A, CAIRA MR, ZHANG GG, GRANT DJ.: "Physical properties of parabens and their mixtures: solubility in water, thermal behavior, and crystal structures.", J PHARM SCI., vol. 88, no. 11, November 1999 (1999-11-01), pages 1210 - 1216, XP002631268 *

Also Published As

Publication number Publication date
RU2013123043A (ru) 2014-12-10
JP2013540142A (ja) 2013-10-31
EP2605753A2 (fr) 2013-06-26
PH12013500679A1 (en) 2013-06-10
CA2814975A1 (fr) 2012-04-26
IL225775A0 (en) 2013-09-30
WO2012052478A2 (fr) 2012-04-26
AU2011317642A1 (en) 2013-05-02
BR112013009577A2 (pt) 2016-07-12
SG189338A1 (en) 2013-05-31
CN103313700A (zh) 2013-09-18
MX2013004472A (es) 2013-10-25
ZA201302812B (en) 2014-06-25
KR20130101552A (ko) 2013-09-13

Similar Documents

Publication Publication Date Title
WO2012052479A3 (fr) Compositions de gel de brimonidine et leurs procédés d'utilisation
WO2011082266A3 (fr) Composés hétérocycliques substitués
WO2011060049A3 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
WO2012177844A3 (fr) Composés d'imidazopyridinyle-aminopyridine substitués
WO2011082273A3 (fr) Composés de pyrroloaminopyrimidine substitués
WO2011082270A3 (fr) Composés imidazopyridinyl-aminopyridine substitués
WO2011082267A8 (fr) Composés triazolo-pyrazine substitués
WO2012052478A3 (fr) Composition de gel topique
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2012016186A8 (fr) Inhibiteurs de kinases macrocycliques et leurs utilisations
CA2871471C (fr) Inhibiteurs d'adn pk
CA2894891A1 (fr) Derives d'acide boronique et leurs utilisations therapeutiques
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
WO2011107462A3 (fr) Compositions de protection solaire
WO2012048099A3 (fr) Cellules chargées de nanoparticules
WO2012030984A3 (fr) Compositions pour la peau et leurs applications
WO2010011296A3 (fr) Inhibiteurs de désacétylase et leurs utilisations
WO2012082436A3 (fr) Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
WO2011123678A3 (fr) Composés de benzo-pyrido-triazolo-diazépine substitués
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2012090043A8 (fr) Nouvelles formes à l'état solide d'azilsartan médoxomil et leur procédé de préparation
WO2011085162A3 (fr) Compositions topiques transdermiques de dexmédétomidine et leurs procédés d'utilisation
PH12014501991A1 (en) Phenicol antibacterials
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
WO2015056094A3 (fr) Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent analgésique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11771146

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011771146

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011771146

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12013500679

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2814975

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013534308

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/004472

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011317642

Country of ref document: AU

Date of ref document: 20111019

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137012906

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013123043

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013009577

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013009577

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130419

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载